Immuneering Corp (IMRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Immuneering Corp stock (IMRX) is currently trading at $5.32. Immuneering Corp PS ratio (Price-to-Sales) is 563.62. Analyst consensus price target for IMRX is $17.00. WallStSmart rates IMRX as Sell.
- IMRX PE ratio analysis and historical PE chart
- IMRX PS ratio (Price-to-Sales) history and trend
- IMRX intrinsic value — DCF, Graham Number, EPV models
- IMRX stock price prediction 2025 2026 2027 2028 2029 2030
- IMRX fair value vs current price
- IMRX insider transactions and insider buying
- Is IMRX undervalued or overvalued?
- Immuneering Corp financial analysis — revenue, earnings, cash flow
- IMRX Piotroski F-Score and Altman Z-Score
- IMRX analyst price target and Smart Rating
Immuneering Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Immuneering Corp (IMRX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around return on equity and price/sales. Significant fundamental concerns warrant caution or avoidance.
Immuneering Corp (IMRX) Key Strengths (2)
Trading at 1.48x book value, attractively priced
50.73% held by institutions, strong professional interest
Supporting Valuation Data
Immuneering Corp (IMRX) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -99.80%, a shrinking business
Very expensive at 563.6x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Immuneering Corp (IMRX) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 8.0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (1.48) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Price/Sales. Some valuation metrics including Price/Sales (563.62) suggest expensive pricing. Growth concerns include Revenue Growth at -99.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -43.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -43.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -99.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
IMRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
IMRX's Price-to-Sales ratio of 563.62x sits near its historical average of 563.62x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 563.62x set in Feb 2026, and 0% above its historical low of 563.62x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Immuneering Corp (IMRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Immuneering Corp operates as a stable business with moderate growth and solid fundamentals. Revenue reached 455 with 100% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 2047170% of revenue (9M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -10M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Immuneering Corp.
Bottom Line
Immuneering Corp offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(15 last 3 months)
| Insider | Type | Shares |
|---|---|---|
NEUFELD, LEAH R CHIEF PEOPLE OFFICER | Buy | +3,628 |
| Insider | Type | Shares |
|---|---|---|
BRAKEWOOD, HAROLD EUGENE Chief Business Officer | Buy | +5,250 |
| Insider | Type | Shares |
|---|---|---|
NEUFELD, LEAH R CHIEF PEOPLE OFFICER | Buy | +2,626 |
| Insider | Type | Shares |
|---|---|---|
FEINBERG, PETER Director | Buy | +20,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:25:28 AM
About Immuneering Corp(IMRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Immuneering Corp (IMRX) is a pioneering biotechnology company focused on the development of innovative therapeutics for cancer and other severe diseases using its proprietary drug discovery platforms. By leveraging advanced bioinformatics and machine learning, Immuneering excels in identifying and optimizing drug candidates that precisely target critical biological pathways, thereby enhancing patient outcomes with therapies that are both more effective and less toxic. With a robust pipeline of drug candidates and strategic collaborations, the company is well-positioned to emerge as a leader in the rapidly evolving landscape of personalized medicine and targeted cancer therapies.